nutra pharm cp - NPHC

NPHC

Close Chg Chg %
0.00 -0.00 -99.00%

Closed Market

0.00

0.00 (99.00%)

Volume: 13.38M

Last Updated:

May 22, 2026, 2:15 PM EDT

Company Overview: nutra pharm cp - NPHC

NPHC Key Data

Open

$0.00

Day Range

0.00 - 0.00

52 Week Range

0.00 - 0.01

Market Cap

$0.00

Shares Outstanding

7.16B

Public Float

7.09B

Beta

67.58

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.00

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.41M

 

NPHC Performance

1 Week
 
-99.67%
 
1 Month
 
-99.67%
 
3 Months
 
-99.00%
 
1 Year
 
-99.00%
 
5 Years
 
N/A
 

NPHC Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About nutra pharm cp - NPHC

Nutra Pharma Corp. operates as a bio pharmaceutical company. The firm engages in the acquisition, licensing and commercialization of pharmaceutical products and technologies & homeopathic and ethical drugs for the management of pain, neurological disorders, autoimmune and infectious diseases. Its products are Cobroxin, which is used for an over-the-counter pain reliever designed to treat moderate to severe chronic pain and Nyloxin Extra Strength, which is used for stronger versions of Cobroxin. The company was founded on February 1, 2000 and is headquartered in Boca Raton, FL.

NPHC At a Glance

Nutra Pharma Corp.
6400 Park of Commerce Blvd
Boca Raton, Florida 33487
Phone 1-954-509-0911 Revenue 385.31K
Industry Pharmaceuticals: Major Net Income -2,047,392.00
Sector Health Technology Employees 7
Fiscal Year-end 12 / 2026
View SEC Filings

NPHC Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 2.019
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -8.90
Enterprise Value to Sales 31.435
Total Debt to Enterprise Value 0.937

NPHC Efficiency

Revenue/Employee 55,043.857
Income Per Employee -292,484.571
Receivables Turnover 1.028
Total Asset Turnover 0.651

NPHC Liquidity

Current Ratio 0.027
Quick Ratio 0.025
Cash Ratio 0.002

NPHC Profitability

Gross Margin 51.032
Operating Margin -379.526
Pretax Margin -531.366
Net Margin -531.366
Return on Assets -345.828
Return on Equity N/A
Return on Total Capital 37.407
Return on Invested Capital N/A

NPHC Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital -207.406
Total Debt to Total Assets 1,941.978
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital -2.497
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Nutra Pharm Cp - NPHC

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
438.27K 594.88K 392.15K 385.31K
Sales Growth
+348.43% +35.73% -34.08% -1.74%
Cost of Goods Sold (COGS) incl D&A
283.06K 275.85K 144.83K 188.68K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
116.49K 95.62K 91.18K 101.43K
Depreciation
116.49K 95.62K 91.18K 101.43K
Amortization of Intangibles
- - - -
-
COGS Growth
+97.16% -2.55% -47.50% +30.28%
Gross Income
155.21K 319.03K 247.32K 196.63K
Gross Income Growth
+438.64% +105.54% -22.48% -20.50%
Gross Profit Margin
+35.41% +53.63% +63.07% +51.03%
2022 2023 2024 2025 5-year trend
SG&A Expense
2.06M 1.21M 1.13M 1.66M
Research & Development
- - - -
-
Other SG&A
2.06M 1.21M 1.13M 1.66M
SGA Growth
+6.18% -41.53% -6.66% +47.37%
Other Operating Expense
- - - -
-
Unusual Expense
(10.86M) 179.68K 187.12K 203.74K
EBIT after Unusual Expense
8.95M (1.07M) (1.07M) (1.67M)
Non Operating Income/Expense
16.21K 73.06K 103.45K 58.75K
Non-Operating Interest Income
16.21K 73.06K 103.45K 58.75K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
791.48K 399.76K 323.57K 440.06K
Interest Expense Growth
+59.68% -49.49% -19.06% +36.00%
Gross Interest Expense
791.48K 399.76K 323.57K 440.06K
Interest Capitalized
- - - -
-
Pretax Income
8.18M (1.39M) (1.29M) (2.05M)
Pretax Income Growth
+162.44% -117.04% +7.73% -59.25%
Pretax Margin
+1,865.70% -234.22% -327.85% -531.37%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
8.18M (1.39M) (1.29M) (2.05M)
Minority Interest Expense
- - - -
-
Net Income
8.18M (1.39M) (1.29M) (2.05M)
Net Income Growth
+162.44% -117.04% +7.73% -59.25%
Net Margin Growth
+1,865.70% -234.22% -327.85% -531.37%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
8.18M (1.39M) (1.29M) (2.05M)
Preferred Dividends
- - - -
-
Net Income Available to Common
8.18M (1.39M) (1.29M) (2.05M)
EPS (Basic)
0.0011 -0.0002 -0.0002 -0.0003
EPS (Basic) Growth
- +161.11% -118.18% -50.00%
Basic Shares Outstanding
7.50B 7.61B 7.67B 7.78B
EPS (Diluted)
0.0004 -0.0002 -0.0002 -0.0003
EPS (Diluted) Growth
- +122.22% -150.00% -50.00%
Diluted Shares Outstanding
19.10B 7.61B 7.67B 7.78B
EBITDA
(1.79M) (791.36K) (787.24K) (1.36M)
EBITDA Growth
+6.97% +55.81% +0.52% -72.87%
EBITDA Margin
-408.63% -133.03% -200.75% -353.20%

Nutra Pharm Cp in the News